This small-cap pharma stock engaged in the development, manufacturing, and marketing of vaccines, pharmaceutical products, and biotechnology solutions, serving global markets in various therapeutic areas, hit a 5 percent upper circuit after receiving an additional order worth $5.20 million from the United Nations International Children’s Emergency Fund (UNICEF) for the supply of 40 million doses of its bivalent oral polio vaccine (bOPV).
Stock Price Movements
With a market capitalization of Rs. 3,300.80 crores, the shares of Panacea Biotec Limited hit a 5 percent upper circuit of Rs. 538.90 per share on Thursday, up from its previous closing price of Rs. 513.25 per share.
What Happened
Panacea Biotec Limited has received an additional award from the United Nations International Children’s Emergency Fund (UNICEF) for the supply of 40 million doses of its bivalent oral polio vaccine (bOPV), valued at approximately US$ 5.20 million (approx. Rs. 44 Crore), to be delivered in Q3 CY2025.
This follows the earlier award, announced on December 24, 2024, for 115 million doses of bOPV worth approximately US$ 14.95 million (approx. Rs. 127 Crore) for the same financial year. The company will continue to fulfill its commitments under the existing Long-Term Arrangement with UNICEF, with both contracts to be publicly disclosed by UNICEF on its website.
Manufacturing Facilities
The company operates cGMP-compliant manufacturing facilities across India, including pharmaceutical and oncology facilities in Baddi, Himachal Pradesh, and a drug substance facility in Lalru, Punjab. It also has vaccine manufacturing, drug product, and nutrition product facilities with certifications from the US FDA, WHO, FSSAI, BIS, and ISO.
Also read: Bajaj Group stock jumps 4% after board sets date to consider bonus shares, stock split and dividend
Global Presence
Panacea Biotec products are exported to over 89 countries, including the USA, Canada, Germany, Saudi Arabia, Vietnam, and Brazil. These products cater to various therapeutic areas, including nutrition, immunisation, oncology, nephrology, diabetes, and gastroenterology.
Recent quarter results
Panacea Biotec Limited’s revenue has increased from Rs. 150.50 crore in Q3 FY24 to Rs. 163.49 crore in Q3 FY25, which has grown by 8.63 percent. The net loss of the company turned into net profit, from Rs. -2.20 crore in Q3 FY24 to Rs. 4.44 crore in Q3 FY25.
Company Overview
Panacea Biotec Limited is a global pharmaceutical and biotechnology company headquartered in New Delhi, India, with principal offices in Mumbai and Lalru near Chandigarh. The company was founded in 1984 and specializes in the research, development, manufacturing, and marketing of vaccines, pharmaceutical formulations, biosimilars, nutraceuticals, and natural products
Written By – Nikhil Naik
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
